Chronic Myeloid Leukemia
Specialty Channel

Featured Article
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug…
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns…
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Which clinical trial displayed results that were in favor of imatinib, both in terms of efficacy and tolerability, for chronic myeloid leukemia?
True or False: The administration of low-dose TKIs before TKI cessation impairs treatment‐free remission in patients with CML.
True or False: Switching from imatinib to dasatinib, in cases of suboptimal response, may offer clinical benefit in patients with CML.

News

Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
Asciminib is well-tolerated and shows promising clinical activity in patients with Ph+ CML with baseline BCR-ABL1 levels less than 1%.

Interactive Features

Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug…
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns…
Stay in the know.
OncNet Newsletter